for adults with an advanced lung cancer called "squamous non-small cell", previously treated with platinum-based chemotherapy, it's not every day something this big comes along. a chance to live longer with... opdivo, nivolumab. opdivo is the first and only immunotherapy fda-approved based on a clinical trial demonstrating longer life... ...for these patients. in fact, opdivo significantly increased the chance of living longer versus chemotherapy. opdivo is different. it works with your immune system. opdivo can cause your immune system to attack normal organs and tissues in your body and affect how they work. this may happen any time during or after treatment has ended, and may become serious and lead to death.